Sihuan Pharmaceutical (00460.HK): Xuanzhu Biotechnology's self-developed innovative drug Deloyacil tablets obtained approval from the National Medical Products Administration for marketing.

News from the Securities Times APP, Si Huan Pharmaceuticals (00460.HK) announced that its non-wholly owned subsidiary Xuanzhu Biotechnology Co., Ltd. (Xuanzhu Biotechnology) has independently developed an ALK inhibitor class 1 innovative drug, deloac tablet (formerly known as "daxitinib", XZP-3621, trade name: Xuanfeining), which has been approved for market by the National Medical Products Administration of China (NMPA) for the treatment of advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) positive. This product is the third class 1 innovative drug approved for market by Xuanzhu Biotechnology, and also the second class 1 innovative tumor drug approved for market by Xuanzhu Biotechnology, marking the continuous breakthrough in its R&D in the field of oncology from targeted therapy for breast cancer to lung cancer.